Search

EHA-SWG Scientific Meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid Leukemias

Dates: April 25-26, 2025
Location: to be announced
Chairs: K Döhner, P Vyas, and MT Voso
Collaborating SWG: EHA Specialized Working Group on Acute Myeloid Leukemia

Registration will be open soon

Program The EHA-SWG scientific meeting on Recent Advances in the Pathogenesis and Treatment of Secondary Acute Myeloid…

Read more

EHA-PTHiT Hematology Mini Tutorial

Dates: April 12-13, 2021
Location: VIRTUAL
Chairs: I Hus (Poland), T Robak (Poland) & G Gaidano (Italy)

As a prelude to the full Tutorial planned for later this year, EHA and the Polish Society of Hematology and Transfusion (PTHiT) present a virtual 'mini…

Read more

Publications

Original scientific publications
Lymphopenia confers poorer prognosis in Myelodysplastic Syndromes with very low and low IPSS-M
Fandrei D, Huynh T, Sébert M, Aguinaga L, Bisio V, Kim R, Clappier E, Espéli M, Balabanian K, Moins-Teisserenc H, Toubert A, Dulphy N, Fenaux…

Read more

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

ABT-199: Novel Bcl-2 specific inhibitor updated results confirm substantial activity and durable responses in high-risk CLL.

Chronic Lymphocytic Leukaemia (CLL) is the most common leukemia in adults in the Western world and is diagnosed in approximately 5 persons per 100,000 population per year.

Read more